Dengue vaccine: local decisions, global consequences

Area of Science:

• Vaccinology
• Infectious Diseases
• Public Health Policy

Background:

• New vaccines for diseases in low- and middle-income countries present regulatory challenges.
• The chimeric tetravalent, live-attenuated dengue vaccine (CYD-TDV) has been approved in five countries.
• CYD-TDV demonstrates partial and heterogeneous efficacy with potential adverse effects.

Purpose of the Study:

• To evaluate the safety and efficacy of the CYD-TDV dengue vaccine.
• To assess the long-term safety profile, particularly in seronegative individuals.
• To inform cautious deployment and policy decisions regarding dengue vaccination.

Main Methods:

• Analysis of clinical trial data for CYD-TDV.
• Comparison of dengue hospitalization rates between vaccinated and control groups.
• Assessment of age and serostatus as factors in vaccine adverse events.

Main Results:

• In trials, children aged 2-5 years at first vaccination had a sevenfold increased risk of dengue hospitalization by year three.
• The long-term safety in seronegative individuals remains unclear.
• Heterogeneous efficacy and potential for increased disease severity in certain populations were observed.

Conclusions:

• Cautious deployment of CYD-TDV is recommended, requiring rigorous risk-benefit evaluation.
• Long-term monitoring of vaccine effects is essential.
• Dengue vaccine implementation should not detract from essential preventive measures against mosquito-borne diseases.